Interestingly, two weeks after doxycycline indication, the EGFR L8585R mutants showed diffuse lung cancer that resembled human bronchioalveolar carcinoma in contrast to the mutant-deletion mice (EGFR DeltaL747-S752) that developed multifocal tumors embedded in normal lung parenchyma. The gene discussed is EGFR; the disease is lung adenocarcinoma in situ.